Justice Ketanji Brown Jackson authored an opinion joined by the court’s eight other members and handed down on Thursday in a closely watched case involving a dispute over pharmaceutical patents.
The justices ruled unanimously in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., reversing a lower court decision and sending the case back for further proceedings.
Advertisement
The decision was notable because Jackson is a frequent dissenter from the remainder of the court, whereas this ruling was unanimous.
The ruling gives important guidance on when patent-infringement claims against generic drug manufacturers can move forward.
The ruling particularly helps cases with so-called “skinny labels”—FDA-approved labels that leave out patented uses of a medication while allowing generic versions to be sold for non-patented purposes.
Beyond the immediate dispute, the decision could have major repercussions for the pharmaceutical industry and consumers alike.
By clarifying the legal standards for generic drug marketing and patent liability, the Court’s ruling is expected to affect how quickly lower-cost alternatives reach the marketplace and how manufacturers describe the uses and risks of their products.
Advertisement
The stakes are substantial because generic medications account for the overwhelming majority of prescriptions filled in the United States.
Industry groups and generic-drug manufacturers warned that a ruling favoring Amarin could have exposed generic companies to greater litigation risk, potentially discouraging market entry and delaying competition that typically drives down prescription drug costs, Newsweek reported.
The ruling also serves as a reminder that many Supreme Court cases do not fit neatly into the partisan narratives that often dominate coverage of the Court.
While the most politically charged disputes frequently generate 6-3 ideological splits, a substantial share of the Court’s docket is still resolved unanimously or by broad bipartisan coalitions of justices.
The case also highlights the evolving position of Justice Ketanji Brown Jackson on the Court.
According to statistics from the Court’s 2024-25 term, Jackson was part of the majority in roughly 72 percent of decided cases, the lowest rate among the nine justices during that period, noted Newsweek.
“A federal district court dismissed the case, but the U.S. Court of Appeals for the Federal Circuit allowed it to proceed, finding the allegations plausible,” the outlet reported.
“The case is part of an ongoing effort by the court to clarify how patent law applies to generic drugs under the Hatch-Waxman Act, which governs competition between brand-name and generic pharmaceuticals,” it said.
The Supreme Court has recently agreed to reassess a longstanding immigration policy that barred asylum seekers from entering at ports along the southern U.S. border.
President Donald Trump petitioned the justices to examine a Ninth Circuit decision that classified the policy as illegal.
The Biden administration abolished the practice known as “metering.”
The Trump administration aims to preserve adaptability while augmenting its immigration enforcement initiatives.
Earlier this year, U.S. Solicitor General John Sauer asserted, “The Constitution delegates the power to regulate the border to the political branches, not the judiciary.”
Sauer asserted that the ruling undermines Congress’s authority to formulate asylum policy, citing its connection to existing policies.
It also substantially infringes upon the executive branch’s authority to regulate the nation’s borders.
Sauer asserted, “Based on the reasoning of the decision below, [Customs and Border Patrol] was barred from impeding the entry of an individual who presented themselves at the border without a prior appointment.”
“An alien may claim to have arrived ‘in the United States,’ thereby requiring governmental inspection and processing of his asylum application, which would allow him to bypass the queue,” Sauer added.
“The asylum-seekers challenged the government’s petition, claiming that the appellate court’s ruling applied exclusively to a particular cohort of migrants,” Sauer continued.
The Immigration and Nationality Act mandates that individuals within the United States, regardless of their location, possess the right to seek asylum if they can demonstrate a well-founded fear of persecution in their country of origin.
This article may contain commentary which reflects the author’s opinion.
